Non-muscle Invasive Bladder Cancer (NMIBC) Clinical Trial
Official title:
Demonstration of the Medical Interest of the VisioCyt® Artificial Intelligence Test
European, multicenter clinical trial with VisioCyt®, an in vitro diagnostic medical device. VisioCyt® is an innovative solution for the early diagnosis of bladder cancer.
VisioCyt® is based on a patented technology, combining bright-field imaging and artificial intelligence, from a simple urine sample from which the cells are extracted . The main objective of the study is to demonstrate the medical superiority of the VisioCyt® test versus conventional cytology for detecting recurrence of bladder tumors, in patients monitoring non-muscle infiltrating bladder tumors at high and very high risk of progression ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT03839472 -
Continuous Bladder Irrigation Following Transurethral Resection of Bladder Tumors
|
N/A | |
| Completed |
NCT03672240 -
Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04179162 -
Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment
|
Phase 1/Phase 2 | |
| Terminated |
NCT03719300 -
Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC
|
Phase 2 | |
| Terminated |
NCT03167151 -
Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03148158 -
Assessment Of Bladder Tumors Stage And Grade By Outpatient Flexible Cystoscopy Performed By Urology Resident
|
N/A | |
| Terminated |
NCT06069453 -
Hyaluronic Acid Sodium Salt and Hydeal-D in the Management of LUTS After TURBT for NMIBC.
|
N/A | |
| Completed |
NCT02009332 -
Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer
|
Phase 1/Phase 2 |